Members Only Content

Subscribe to get full access

Free Preview

Shockwave Medical (Nasdaq: SWAV), the innovative leader in intravascular lithotripsy, has received a $335 per share all-cash acquisition offer from Johnson & Johnson (NYSE: JNJ). 

Shockwave Medical (Nasdaq: SWAV), the innovative leader in intravascular lithotripsy, has received a $335 per share all-cash acquisition offer from Johnson & Johnson (NYSE: JNJ). 

We have been longtime fans of this three-time 7investing recommendation and we expect the deal will go through.

On a recent exclusive livestream, our advisors Luke Hallard and Simon Erickson described several nuances related to the offer. The two also share what they expect for investors going forward.

https://spotifyanchor-web.app.link/e/YzUx5A3GyIb

Publicly-traded companies mentioned in this podcast include ShockWave Medical and Johnson & Johnson. 7investing’s advisors and/or its guests may have positions in the companies that are mentioned.

Don’t miss out on future conversations like this! 7investing has recently published interviews with the CEOs of PubMatic, Rocket Lab, and more. Join 7investing’s free email list to get our podcasts and investing insights delivered directly to your Inbox.

related news & insights

  • 7investing logo next to the Upstart logo.
    June 12, 2025||0 min||||

    Upstart Deep Dive: June 2025

    Upstart Recommendation Report Upstart Presentation Slides

  • May 30, 2025||0.8 min||||

    7investing Exclusive: A Deep Dive Into Lemonade

    Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]

  • May 16, 2025||46.1 min||||

    What’s Next for Digital Advertising? 7investing Interviews PubMatic CEO Rajeev Goel

    PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]